益生菌对恶性肿瘤患者化疗和放疗相关腹泻的影响:一项基于随机对照试验的Meta分析

发布时间：2018-11-20 14:03

【摘要】：目的:评价益生菌类制剂能否有效降低恶性肿瘤患者化疗和放疗相关腹泻发生率。方法:检索PubMed、Embase、ClinicalTrials.gov、Cochrane Library文献数据库,查找截至2017年1月的采用益生菌类制剂治疗恶性肿瘤患者化疗和放疗相关腹泻的随机对照试验研究。对筛选出的文献进行质量评价。采用Stata 12.0软件进行Meta分析,Egger检验判断发表偏倚。结果:共纳入9篇随机对照研究文献。735例恶性肿瘤患者在化疗和放疗后接受益生菌治疗,695例恶性肿瘤患者接受安慰剂治疗。Meta分析结果显示,恶性肿瘤患者在化疗和放疗后接受益生菌治疗相较于对照组,可显著降低33%的腹泻发生率(95%可信区间:13%~49%;P=0.003);其中,放疗相关腹泻发生率显著减少31%(95%可信区间:7%~49%)(P=0.020),化疗相关腹泻发生率减少53%(95%可信区间:37%~84%)(P=0.170)。结论:恶性肿瘤患者在化疗和放疗后接受益生菌治疗能够显著减少相关腹泻发生率,主要表现为降低放疗相关腹泻发生率,而对于是否能减少化疗相关腹泻发生率,仍需要进一步的证据支持。
[Abstract]:Objective: to evaluate whether probiotics can effectively reduce the incidence of chemotherapy and radiotherapy associated diarrhea in malignant tumor patients. Methods: the PubMed,Embase,ClinicalTrials.gov,Cochrane Library literature database was searched to find out the randomized controlled trial of chemotherapy and radiotherapy associated diarrhea in patients with malignant tumor treated with probiotics as of January 2017. The quality of the selected documents was evaluated. Stata 12.0 software was used for Meta analysis and Egger test was used to judge publication bias. Results: a total of 9 randomized controlled study papers were included. 735 patients with malignant tumor received probiotic therapy after chemotherapy and radiotherapy, and 695 patients with malignant tumor received placebo therapy. The results of Meta analysis showed that 735 patients were treated with probiotics after chemotherapy and radiotherapy, and 695 patients with malignant tumor received placebo therapy. Compared with the control group, the incidence of diarrhea in malignant tumor patients treated with probiotics after chemotherapy and radiotherapy was significantly decreased by 33% (95% CI: 13%: 49%). The incidence of radiotherapy-associated diarrhea decreased by 31% (95% CI: 7%) (P0. 020), and the incidence of chemotherapy-associated diarrhea decreased by 53% (95% CI: 37%) (P0. 170). Conclusion: probiotic therapy after chemotherapy and radiotherapy can significantly reduce the incidence of associated diarrhea in patients with malignant tumors, mainly in the reduction of the incidence of radiotherapy-associated diarrhea, and whether the incidence of chemotherapy-associated diarrhea can be reduced. Further evidence is still needed.
【作者单位】：天津市河西区疾病预防控制中心慢病科;天津医科大学附属肿瘤医院研究所流行病与生物统计室;
【分类号】：R730.5

【参考文献】